![Bethany Sensenig](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 33 977 $ in data 31/05/2026
Bethany L.
Sensenig is currently Independent Director at Supernus Pharmaceuticals, Inc. since 2023, Independent Director at Alpha Cognition, Inc. starting in 2026, and Chief Executive & Financial Officer at Naia Rare Diseases LLC.
Former roles include Independent Director at KalVista Pharmaceuticals, Inc. from 2025 to 2026, Vice President-Finance & Commercial Operations at Biogen, Inc. from 2006 to 2019, Chief Financial Officer at Radius Health, Inc. from 2023 to 2026, Chief Executive & Financial Officer at 9 Meters Biopharma, Inc. in 2023, and Chief Financial Officer & Head-US Operations at Minovia Therapeutics Ltd. from 2019 to 2022.
Education includes undergraduate studies at Montreat College and an MBA from Western Carolina University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
ALPHA COGNITION INC 0,03% | 16/04/2026 | 5.489 ( 0,03% ) | 33 977 $ | 31/05/2026 |
| 29/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 21/08/2023 |
| ALPHA COGNITION INC. | Direttore/Membro del Consiglio | 15/04/2026 |
Naia Rare Diseases LLC
 Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Manufactures biopharmaceutical products | Amministratore Delegato | - |
| Società | Posizione | Fine |
|---|---|---|
| KALVISTA PHARMA | Direttore/Membro del Consiglio | 11/06/2026 |
| RADIUS HEALTH, INC. | Direttore Finanziario/CFO | 01/04/2026 |
| 9 METERS BIOPHARMA, INC. | Amministratore Delegato | 17/07/2023 |
Minovia Therapeutics Ltd.
 Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops mitochondrial cell therapies for clinical-stage biotechnology company | Direttore Finanziario/CFO | 01/01/2022 |
| BIOGEN INC. | Corporate Officer/Principal | 01/03/2019 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes bone health and related therapeutics | Health Technology |
Montreat College
 Montreat College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Western Carolina University
 Western Carolina University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Supernus Pharmaceuticals, Inc.
 Supernus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of central nervous system diseases | Health Technology |
KalVista Pharmaceuticals, Inc.
 KalVista Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets small molecule protease inhibitors for diseases | Health Technology |
9 Meters Biopharma, Inc.
 9 Meters Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals for people with rare digestive diseases and gastrointestinal conditions | Health Technology |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops mitochondrial cell therapies for clinical-stage biotechnology company | Health Technology |
Naia Rare Diseases LLC
Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Manufactures biopharmaceutical products | Health Services |
Alpha Cognition, Inc.
 Alpha Cognition, Inc. Financial ConglomeratesFinance Develops pharmaceutical products for treating neurodegenerative diseases | Finance |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
